HEC-1-B Xenograft Model Service for Endometrial Cancer

The HEC-1-B xenograft model offers a robust and well-characterized platform for preclinical evaluation of endometrial cancer therapeutics, enabling reliable assessment of tumor growth dynamics, drug efficacy, and biological response in an immunodeficient host environment. Alfa Cytology provides comprehensive HEC-1-B xenograft model services, leveraging validated protocols and rigorous quality control to support your endometrial cancer drug development programs from early-stage screening through advanced pharmacological studies.

Overview of HEC-1-B Xenograft Model for Endometrial Cancer

The HEC-1-B cell line is a human endometrial adenocarcinoma-derived model originally established in 1968 by H. Kuramoto from a 71-year-old female patient. As a substrain of HEC-1-A, HEC-1-B exhibits distinct phenotypic characteristics including a stationary growth period between the 135th and 190th days in culture, after which cells appear flattened and more pavement-patterned compared to the parent line. The cell line demonstrates potent tumorigenic activity in immunodeficient mice, forming moderately well-differentiated adenocarcinomas consistent with grade II endometrial carcinoma. Genetically, HEC-1-B displays a diploid to tetraploid karyotype with large submetacentric marker chromosomes, and exhibits low expression of progesterone receptor B (PR-B) and estrogen receptor-alpha (ER-alpha), features associated with high tumorigenic potential in type I endometrial cancer cell lines.

In xenograft applications, HEC-1-B serves as a powerful preclinical model for studying endometrial cancer progression, hormone-related therapeutic responses, and metastatic behavior. The cell line expresses estrogen and progesterone receptors, making it particularly valuable for evaluating hormonal regulation pathways and anti-hormonal therapies. Its epithelial morphology, high proliferative capacity, and established tumorigenicity in nude mice (with 100% tumor take rates reported in subcutaneous implantation studies) provide researchers with a consistent and reproducible system for investigating molecular mechanisms of carcinogenesis, testing novel chemotherapeutic agents, and modeling resistance mechanisms in reproductive oncology research.

Figure 1. Isoalantolactone inhibits the proliferation of HEC-1-B endometrial cancer cells. (Hu, Fang, et al., 2022)

Cell Line Information: HEC-1-B

HEC-1-B is a well-established human endometrial adenocarcinoma cell line with extensive characterization in both in vitro and in vivo settings. The following table summarizes the key biological and genetic characteristics of this model:

Our Services

Alfa Cytology offers end-to-end HEC-1-B xenograft model services tailored to your preclinical research objectives, encompassing cell line authentication, model establishment, in-life monitoring, endpoint analysis, and comprehensive data reporting. Our experienced scientific team ensures reproducible tumor formation, standardized protocols, and flexible study designs to accelerate your endometrial cancer therapeutic development pipeline.

Workflow of HEC-1-B Xenograft Model Construction

The construction of HEC-1-B xenograft models follows a standardized, multi-step workflow designed to ensure consistent tumor formation, reliable data generation, and ethical compliance throughout the preclinical study. Each phase is carefully monitored to maintain model integrity and experimental validity.

1. Cell Culture and Preparation: HEC-1-B cells are maintained in vitro under optimal conditions (EMEM supplemented with 10% fetal bovine serum at 37 degrees C, 5% CO2). Prior to implantation, cells undergo quality control screening for mycoplasma, fungi, yeast, and bacterial contamination, and are harvested at logarithmic growth phase to ensure high viability.
2. Cell Suspension Preparation: Harvested cells are washed, counted, and resuspended in sterile phosphate-buffered saline (PBS) or a suitable matrix (such as Matrigel) at a concentration typically ranging from 5 x 10^6 to 1 x 10^7 cells per 100-200 microL injection volume, depending on the specific study design and implantation site.
3. Animal Preparation and Implantation: Immunodeficient mice (commonly BALB/c nude mice or NSG mice, 6-8 weeks old, 18-20g body weight) are acclimatized and randomized into study groups. HEC-1-B cell suspension is injected subcutaneously into the right flank or orthotopically into the uterine horn, depending on the research objectives.
4. Tumor Monitoring and Measurement: Tumor development is monitored through regular palpation and caliper measurements beginning 5-7 days post-implantation. Tumor volume is calculated using the formula V = (L x W^2)/2, where L represents the longest diameter and W represents the perpendicular width. Measurements are recorded at defined intervals (typically every 2-3 days).
5. Study Intervention and Treatment: Once tumors reach the predetermined volume (typically 100-200 mm^3), animals are randomized into treatment and control groups. Test compounds are administered according to the study protocol, with dosing schedules tailored to the pharmacokinetic profile of the therapeutic agent.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E staining), immunohistochemistry (Ki-67, CD31, hormone receptors), Western blot, flow cytometry, and molecular profiling. Blood samples may be collected for pharmacokinetic and biomarker studies.

Figure 2: Schematic workflow illustrating the derivation and construction of the HEC-1-B Xenograft Model at Alfa Cytology.

Case Study-HEC-1-B Xenograft Model Development

In a representative preclinical study, HEC-1-B xenograft models were successfully established in immunodeficient mice with consistent tumor take rates and predictable growth kinetics. Subcutaneous implantation of HEC-1-B cells resulted in robust tumor formation within 10-15 days, with tumors exhibiting histopathological features consistent with moderately well-differentiated endometrial adenocarcinoma. The model demonstrated dose-dependent responses to reference compounds, with measurable changes in tumor volume, proliferation markers (Ki-67), and angiogenic factors (VEGF, CD31) observed across treatment cohorts. Pharmacodynamic analyses revealed modulation of key signaling pathways relevant to endometrial cancer progression, supporting the utility of this model for evaluating novel therapeutic strategies. Detailed quantitative data and statistical analyses are available upon request and can be customized to align with specific study requirements.

Why Choose Alfa Cytology?

Alfa Cytology delivers reliable, high-quality HEC-1-B xenograft model services backed by scientific expertise, rigorous quality standards, and a commitment to accelerating your preclinical research. Our integrated approach ensures data integrity, regulatory compliance, and seamless project execution from study design to final reporting.

• Validated HEC-1-B cell line authentication and mycoplasma-free certification ensure model reliability and reproducibility.
• Standardized xenograft protocols with documented tumor take rates and growth kinetics minimize experimental variability.
• Flexible study designs accommodate diverse therapeutic modalities including small molecules, biologics, antibody-drug conjugates, and combination regimens.
• Comprehensive endpoint analysis capabilities spanning histopathology, immunohistochemistry, biomarker profiling, and molecular characterization.
• Experienced project management team provides timely progress updates, transparent communication, and customized reporting formats.
• Competitive timelines and cost-effective pricing structures designed to support both exploratory screening studies and advanced pharmacology programs.
• Strict adherence to animal welfare guidelines and regulatory standards ensures ethical conduct and audit-ready documentation.

Contact Us

Ready to advance your endometrial cancer research with our HEC-1-B xenograft model services? Contact us today to discuss your project requirements, receive a customized study proposal, or schedule a consultation with our scientific team. Whether you need a standard xenograft study or a complex, multi-arm pharmacology program, Alfa Cytology is here to support your preclinical development goals---reach out to us and let's build your next study together.

For research use only. Not intended for any clinical use.